Which patient subgroups, based on the LEADER trial, are most likely to benefit from liraglutide therapy? High risk? Low risk? Both? At what point in the natural history of T2D? Early? Late? Both?

Which patient subgroups, based on the LEADER trial, are most likely to benefit from liraglutide therapy? High risk? Low risk? Both? At what point in the natural history of T2D? Early? Late? Both?

Which patient subgroups, based on the LEADER trial, are most likely to benefit from liraglutide therapy? High risk? Low risk? Both? At what point in the natural history of T2D? Early? Late? Both?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Steve Bain, MD

Steve Bain, MD

Professor of Medicine (Diabetes)
College of Medicine
Swansea University
Swansea, UK